340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

In Reversal, Amgen Decides to Continue Offering 340B Pricing on Orphan Drugs

Decision announced soon after interpretive rule's release
 

Print Article

July 31, 2014—In response to the Health Resources and Services Administration’s new 340B orphan drug exclusion interpretive rule, the biopharmaceutical manufacturer Amgen has decided to continue providing 340B pricing on its orphan-designated products to critical access hospitals, sole community hospitals, rural referral centers, and free-standing cancer hospitals. 


You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.    Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

LATEST ARTICLES DELIVERED

Get new article alerts via email.

This field is required.

Check your inbox or spam folder now to confirm your subscription.

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS feed: 340B Employed 340B Employed

  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Specialist | Vail Health November 17, 2026
  • Pharmacy Manager, 340B Program | Tufts Medical Center November 11, 2026
  • 340B Program Pharmacy Manager | Allies for Health + Wellbeing November 10, 2026

Copyright © 2026 · 340B Health